TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE, TSX: BVF) today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act has expired with respect to the acquisition of U.S. rights to Wellbutrin XL® (bupropion hydrochloride extended-release tablets) by its subsidiary, Biovail Laboratories International SRL, from GlaxoSmithKline plc (GSK).